This site is intended for Healthcare professionals only.

Aurobindo Pharma gets USFDA nod to market kidney ailment drug


Aurobindo Pharma gets USFDA nod to market kidney ailment drug

New Delhi: Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Sevelamer Carbonate tablets in the American market.

The tablets are indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.

“The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg,” Aurobindo Pharma said in a BSE filing.



Source: PTI
0 comment(s) on Aurobindo Pharma gets USFDA nod to market kidney ailment drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted